Hong Kong Stock Movement: VIGONVITA-B's share price surged 10.12%. Can the layout of innovative drugs offset the impact of financial losses?

Hong Kong Stock Movement

VIGONVITA-B rose by 10.12%. Based on recent news,

1. On November 10, VIGONVITA-B's stock price fell over 22% in the afternoon, hitting a low of HKD 51.2 during the session, still 53% higher than the IPO price. The company focuses on three major treatment areas: neuropsychiatry, reproductive health, and viral infections. Recent financial data shows a decline in revenue, leading to a loss of market confidence.

2. On November 10, VIGONVITA-B's financial report indicated a net loss of RMB 218 million for 2024, compared to a net profit of RMB 6.427 million in 2023. The decline in revenue is considered the main reason for the loss, affecting investor sentiment.

3. On November 10, VIGONVITA-B's innovative drug pipeline and generic drug sector layout attracted market attention. The company has established 9 innovative pipelines, with 2 in the commercialization stage, 4 in the clinical stage, and 3 in the preclinical stage, showing potential for future growth. The pharmaceutical industry's competition in innovative drug R&D is intense.

Stocks with High Trading Volume in the Industry

Shijiazhuang Pharmaceutical Group fell by 0.26%. Based on recent key news:

1. On November 8, Shijiazhuang Pharmaceutical Group faced market concerns regarding its transformation into innovative drugs. Although the company stated that penalties do not affect business operations, there are still doubts about the progress of its innovative drug transformation, putting pressure on the stock price. According to statistics from YaoMingMofang Invest, Shijiazhuang Pharmaceutical Group's R&D expenses accounted for 11.8% of sales in 2021, indicating a certain level of R&D investment capability, but still lagging behind international leaders. The pharmaceutical industry's R&D investment has grown significantly.

China Biopharmaceutical fell by 1.44%, with a trading volume of HKD 83.45 million, and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation.

United Pharmaceutical rose by 1.52%. Based on recent news,

1. On November 10, United Pharmaceutical announced that its wholly-owned subsidiary Zhuhai United Pharmaceutical Co., Ltd. has completed Phase II clinical research of its self-developed Class I innovative drug TUL01101 tablets in adult subjects with moderate to severe atopic dermatitis in China. The trial results showed significant efficacy across all dosage groups, effectively clearing skin lesions, alleviating itching, and improving the quality of life for subjects. This news boosted market confidence and drove the stock price up.

2. On November 11, Caihua News reported that United Pharmaceutical's TUL01101 tablets performed excellently in Phase II clinical research, showing significant efficacy and good safety. This news further enhanced investors' confidence in the company's future development, promoting the rise in stock price.

3. On November 10, Economic News reported that United Pharmaceutical's TUL01101 tablets achieved expected goals in Phase II clinical research, supporting its entry into the next stage of clinical research. This news further solidified the market's trust in the company's R&D capabilities, driving the stock price up. The chemical pharmaceutical industry has performed strongly recently, with increased investor confidence Stocks Ranked Among the Top by Market Capitalization in the Industry

Hengrui Medicine fell by 1.12%. Based on recent key news:

1. On November 10, Hengrui Medicine announced that it received approval notices for clinical trials of two drugs from the National Medical Products Administration, including HRS-2430 injection and SHR-4610 injection. This news reflects the company's ongoing investment in innovative drug research and development, with cumulative R&D expenditures of RMB 24.6 million and RMB 7.36 million respectively, driving stock price fluctuations.

2. On November 8, Merck showcased multiple R&D collaborations with Hengrui Medicine at the China International Import Expo, emphasizing a localization integration strategy. This collaboration may enhance Hengrui Medicine's market competitiveness and impact its stock price.

3. On November 10, Hengrui Medicine's subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., received approval for the clinical trial of SHR-4610 injection, which is planned for the treatment of advanced solid tumors, further promoting the company's innovative development in the field of anti-tumor drugs. The pharmaceutical industry is accelerating innovation, and market competition is fierce